GFPC
IBRX icon

Global Financial Private Client’s ImmunityBio IBRX Stock Holding History

Global Financial Private Client’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-32
Closed -$96 – 849
2025
Q1 		$96 Buy
32
+19
+146% +$58 ﹤0.01% 1610
2024
Q4 		$33 Buy
+13
New +$54 ﹤0.01% 1622

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return

Global Financial Private Client's IBRX Position: Q2 2025 in Review

Global Financial Private Client sold out of ImmunityBio (IBRX) in Q2 2025, closing a stake of 32 shares — an estimated $96 sold.

Global Financial Private Client first reported a position in IBRX in Q4 2024 and held it in 2 quarters. The position peaked at $96 in Q1 2025. 241 funds tracked by Wall St. Rank hold IBRX as of Q2 2025.

  • Global Financial Private Client reported no remaining ImmunityBio position as of Q2 2025 after selling out during the quarter.
  • Global Financial Private Client sold 32 ImmunityBio shares in Q2 2025, an estimated $96.
  • Global Financial Private Client first reported a position in ImmunityBio in Q4 2024 and held it in 2 quarters.
  • Global Financial Private Client's ImmunityBio position peaked at $96 in Q1 2025.
  • 241 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2025.

Based on Global Financial Private Client's 13F filing for Q2 2025, filed 10 Jul 2025.